Unlock instant, AI-driven research and patent intelligence for your innovation.
Fused tricyclic compounds as adenosine receptor antagonist
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of compounds and solvates, applied in the field of fused tricyclic compounds
Inactive Publication Date: 2013-08-21
ADVINUS THERAPEUTICS PVT LTD
View PDF28 Cites 4 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Thus, in contrast to the neuroprotection induced by endogenous A1 activation, it appears that A 2A Tonic activation of AR may generate danger signals during injury
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment A1
[0430] Example A1: 5-amino-8-(2-furyl)-3-[2-[4-[4-(2-methoxyethoxy)phenyl]piperazin-1-yl]ethyl ]-1-Methyl-[1,2,4]triazolo[5,1-f]purin-2-one
[0433] A mixture of 4,6-dichloropyrimidine-2,5-diamine (28g, 156mmol), ethanolamine (18ml, 312mmol) and ethanol (250ml) was heated at 100-110°C for 16 hours. The mixture was cooled and the solvent was removed. Methanol (100 ml) was added to the residue and stirred for 20 minutes. The solid was filtered off to obtain 2-[(2,5-diamino-6-chloro-pyrimidin-4-yl)amino]ethanol (22.0 g, 70%).
[0436] A mixture of 2-[(2,5-diamino-6-chloro-pyrimidin-4-yl)amino]ethanol (10.0 g, 49.26 mmol) obtained in step 1 in acetonitrile (400 ml) was cooled to 0°C. To the reaction...
Embodiment B1
[0474] Example B1: 5-amino-8-(2-furyl)-3-[2-[4-[4-(2-hydroxyethoxy)phenyl]piperazin-1-yl]ethyl]- 1-Methyl-[1,2,4]triazolo[5,1-f]purin-2-one
[0475]
[0476] To the compound 5-amino-8-(2-furyl)-3-[2-[4-[4-(2-methoxyethoxy)phenyl]piperazin-1-yl] at 0°C Ethyl]-1-methyl-[1,2,4]triazolo[5,1-f]purin-2-one (Example A1) (0.075g, 0.140mmol) in DCM (10ml) The solution was added dropwise to BBr 3 (0.15ml, 0.154mmol), and stirred at 25°C for 20 hours. use sat.NaHCO 3 (25ml) to quench the reaction mixture and extract with DCM (3 x 20ml). The crude product was purified by column chromatography to obtain 5-amino-8-(2-furyl)-3-[2-[4-[4-(2-hydroxyethoxy)phenyl]piperazine as an off-white solid -1-yl]ethyl]-1-methyl-[1,2,4]triazolo[5,1-f]purin-2-one (70 mg, 90%).
[0486] Step-3: N'-[2-amino-7-(cyclopropylmethyl)-9-(2-hydroxyethyl)-8-oxo-purin-6-yl]furan-2-carbohydrazide (step is identical with step-5 in embodiment A1)
[0487] The crude product was used in the next step.
[0488] Step-4: 5-Am...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The present disclosure relates to fused tricyclic compounds of formula (I) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2A adenosinereceptor antagonists. [Formula should be inserted here] The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2A receptor.; Such conditions include, but are not limited to, Parkinsons disease, restless leg syndrome, Alzheimers disease, neurodegenerative disorder, inflammation, wound healing, dermal fibrosis, nocturnal myoclonus, cerebral ischaemia, myocardial ischemia, Huntington's disease, multiple systematrophy, corticobasal degeneration, Wilson's disease or other disorders of basal ganglia which results in dyskinesias, post traumatic stress disorder, hepatic cirrhosis, sepsis, spinal cord injury, retinopathy, hypertension, social memory impairment, depression, neuroprotection, narcolepsy or other sleep related disorders, attention deficit hyperactivity disorder, drugaddiction, post traumatic stress disorder and vascular injury and the like. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
Description
technical field [0001] The present invention relates to a series of substituted fused tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and Methods of treatment of conditions and diseases mediated by adenosinereceptor (AR) activity. These compounds are useful in the treatment, prevention or inhibition of diseases and disorders which are readily ameliorated by antagonism of adenosine receptors. The invention also relates to processes for the preparation of such compounds and pharmaceutical compositions containing them. Background technique [0002] The actions of adenosine are mediated through at least four specific cell membrane receptors that are currently identified and classified as belonging to the G protein-coupled receptor family A 1 、A 2A 、A 2B and A 3 . A 1 and A 3 The receptor downregulates cellular cAMP levels by coupling to G proteins that inh...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More 
